Soligenix, Inc. (SNGX) stock
SNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.25−0.03 (-9.88%)
Close on Nov 18, 2026Market cap $5.50MP/E –Yield –
Soligenix operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Soligenix's operating income for the twelve months ending Jun 30, 2026 was -$11.04M. For fiscal 2025 it was -$11.85M. The highest annual figure on record is -$2.96M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$11.85M | – |
| FY2024 | Dec 31, 2024 | -$9.44M | – |
| FY2023 | Dec 31, 2023 | -$7.70M | – |
| FY2022 | Dec 31, 2022 | -$14.24M | – |
| FY2021 | Dec 31, 2021 | -$13.10M | – |
| FY2020 | Dec 31, 2020 | -$18.59M | – |
| FY2019 | Dec 31, 2019 | -$10.54M | – |
| FY2018 | Dec 31, 2018 | -$9.06M | – |
| FY2017 | Dec 31, 2017 | -$7.59M | – |
| FY2016 | Dec 31, 2016 | -$5.71M | – |
| FY2015 | Dec 31, 2015 | -$7.11M | – |
| FY2014 | Dec 31, 2014 | -$10.76M | – |
| FY2013 | Dec 31, 2013 | -$7.16M | – |
| FY2012 | Dec 31, 2012 | -$4.69M | – |
| FY2011 | Dec 31, 2011 | -$2.96M | – |
| FY2010 | Dec 31, 2010 | -$7.88M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.10M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.88M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.47M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.76M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.03M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.71M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.87M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.78M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.63M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.57M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.08M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.40M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.19M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.51M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.36M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.23M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.81M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.81M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.47M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.30M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.16M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.92M | – |
| Q2 FY2018 | Jun 30, 2018 | -$1.59M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.39M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.57M | – |
| Q3 FY2017 | Sep 30, 2017 | -$969.62K | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.32M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.74M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.30M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.50M | – |
| Q2 FY2016 | Jun 30, 2016 | -$1.01M | – |
| Q1 FY2016 | Mar 31, 2016 | -$1.91M | – |
See a number that looks wrong?